Extracts:
The clinical objective with Veyonda® is to deliver a form of immuno-oncology therapy considerably better tolerated, more accessible, more cost-effective and more broadly active than current forms of immuno-oncology therapy
DARRT relies on a low dose of radiotherapy to provide the trigger for immune activation, with the role of Veyonda® being to amplify and spread that response to tumours throughout the body.
The DARRT-2 study is a multi-national Phase 2 control-arm study in approximately 200 men with end-stage metastatic castrate-resistant prostate cancer.
Hospital and clinician recruitment will now commence, with all regulatory and ethical approvals to follow. Patient recruitment is anticipated to commence early in the New Year. The trial has a number of in-built milestones that will be reported on over the course of the study.
- Forums
- ASX - By Stock
- NOX
- Ann: Global CRO To Execute DARRT-2 Prostate Cancer Study
Ann: Global CRO To Execute DARRT-2 Prostate Cancer Study, page-2
Featured News
Add NOX (ASX) to my watchlist
|
|||||
Last
6.6¢ |
Change
-0.002(2.94%) |
Mkt cap ! $19.28M |
Open | High | Low | Value | Volume |
6.7¢ | 6.9¢ | 6.6¢ | $13.31K | 198.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1137 | 6.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.7¢ | 22400 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1137 | 0.066 |
1 | 100000 | 0.064 |
3 | 47786 | 0.061 |
4 | 105033 | 0.060 |
2 | 120000 | 0.059 |
Price($) | Vol. | No. |
---|---|---|
0.079 | 12000 | 2 |
0.080 | 12099 | 2 |
0.081 | 22345 | 2 |
0.083 | 40000 | 1 |
0.090 | 25689 | 3 |
Last trade - 15.50pm 28/06/2024 (20 minute delay) ? |
Featured News
NOX (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online